ASP Isotopes updates on PET Labs, helium, Silicon-28; Noble Africa merger with ENDRA on track

ASP Isotopes Inc.

PET Labs 1H 2026 organic revenue growth >50% YoY; FY2026 revenue forecast ~$14M (up from $6M in 2025).
Helium production at Renergen expected to commence before Sept 30, 2026; Phase 1 annualized revenue ~$27M.
Noble Africa reverse merger with ENDRA (NDRA) expected to close in H2 2026; ASPI to own ~89% of combined company.
Silicon-28 enrichment facility operating 48 stages; first commercial shipments of 99% enriched product expected in H2 2026.
QLE convertible notes exchange: ~50% exchanged for ASPI common stock; remaining QLE notes ~$79.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.